Bevacizumab inhibits VEGF, compromising wound healing. Animal studies show it reduces vascular density in capillary beds by 70%. Surgical complications of bevacizumab include proteinuria, bleeding, and delayed wound healing. The risk is highest in the first 6 months and with conditions like peptic ulcers. For elective surgery, withhold bevacizumab for 2-3 half lives (40-60 days) but surgery may be safe after 28 days. Major surgery requires withholding bevacizumab and avoiding anastomoses.